Drugs / Fluoroglutamine
Fluoroglutamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03863457 | Apr 2019 → Dec 2026 expected | breast cancer | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluoroglutamine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03863457 ↗ |
| Known as | [18F](2S, 4R)4-Fluoroglutamine ([18F]F-GLN) | “[18F](2S, 4R)4-Fluoroglutamine ([18F]F-GLN)” NCT03863457 ↗ |
| Known as | [18F]F-GLN | “18F-(2S,4R)4-fluoroglutamine, commonly known as [18F]FGln” PMID 40506235 ↗ Jul 20251“Fluoroglutamine [18F]F-GLN” NCT03863457 ↗ |